Gene therapy for spinal muscular atrophy: timing is key
Open Access
- 21 October 2024
- journal article
- editorial
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 47, 101112
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Clinical Effectiveness of Newborn Screening for Spinal Muscular AtrophyJAMA Pediatrics, 2024
- Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United KingdomThe Lancet Regional Health - Europe, 2023
- P73 Newborn screening programs for spinal muscular atrophy worldwide: are we there yet?Neuromuscular Disorders, 2023
- Combination disease‐modifying treatment in spinal muscular atrophy: A proposed classificationAnnals of Clinical and Translational Neurology, 2023
- Universal newborn screening for spinal muscular atrophy in UkraineThe Lancet, 2023
- Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening—A Systematic ReviewGenes, 2023
- Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screeningDevelopmental Medicine & Child Neurology, 2022
- Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to goNeuromuscular Disorders, 2021
- Time Is Motor Neuron: Therapeutic Window and Its Correlation with Pathogenetic Mechanisms in Spinal Muscular AtrophyMolecular Neurobiology, 2018
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular AtrophyNew England Journal of Medicine, 2017